7 completed, 1 recruiting, 1 withdrawn. 5 Phase 1, 2 Phase 3, 1 Early Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 4, Recruiting 1 |
| Phase 3 | 2 | Completed 1, Withdrawn 1 |
| Early Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
Follow Cinclus Pharma Holding AB: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Maintenance of Healing in Participants With Healed Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD) Linaprazan glurate - High dose, Linaprazan glurate - Low dose, Lansoprazole - Marketed approved dose - GERD (Gastroesophageal Reflux Disease) | Phase 3 | Withdrawn | Cinclus Pharma Holding AB | 2026-03-01 | 2026-05-28 | |
| A Study to Investigate the Effect of Linaprazan Glurate on the Pharmacokinetics of Amoxicillin Drug Drug Interaction - Drug Interaction, GERD (Gastroesophageal Reflux Disease) | Phase 1 | Completed | Cinclus Pharma Holding AB | 12 | 2025-11-11 | 2026-02-27 |
| A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD) Linaprazan glurate 50 mg Twice Daily (BID), Linaprazan Glurate 50 mg Once Daily (QD), Lansoprazole 30 mg Once Daily (QD) - GERD (Gastroesophageal Reflux Disease) | Phase 3 | Completed | Cinclus Pharma Holding AB | 523 | 2025-09-11 | 2026-10-21 |
| Investigate Linaprazan Glurate/Linaprazan in Healthy Subjects linaprazan glurate 25 mg QD, linaprazan glurate 50 mg QD, linaprazan glurate 75 mg QD - GERD | Phase 1 | Completed | Cinclus Pharma Holding AB | 75 | 2023-01-26 | 2025-05-07 |
| Effect of Clarithromycin on PK of Linaprazan, Linaprazan on PK of Clarithromycin and Linaprazan on PK of Midazolam Linaprazan glurate, Drug drug interaction (DDI) - Clarithromycin (Part I), Drug drug interaction (DDI) - Midazolam (Part 2) - Safety Issues, Pharmacokinetics | Phase 1 | Completed | Cinclus Pharma Holding AB | 35 | 2022-11-27 | 2025-01-03 |
| Relative Bioavailability of Linaprazan for the Test Formulation vs. Reference Formulation Linaprazan glurate - Safety, Bioavailability | Phase 1 | Completed | Cinclus Pharma Holding AB | 67 | 2022-11-15 | 2025-04-03 |
| A Study to Investigate the Pharmacokinetics and ECG Effects of Linaprazan Glurate Linaprazan glurate, Placebo - Pharmacokinetics, Cardiodynamic ECG | Phase 1 | Recruiting | Cinclus Pharma Holding AB | 121 | 2022-07-13 | 2026-06-17 |
| A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole X842, X842 Dummy, Lansoprazole - Erosive Esophagitis | Phase 2 | Completed | Cinclus Pharma Holding AB | 248 | 2021-08-11 | 2026-07-01 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of X842 in Human: A Single/Multiple Ascending Dose Study Single ascending dose of X842, Multiple ascending dose of X842, Losec - Healthy Volunteers | Early Phase 1 | Completed | Cinclus Pharma Holding AB | 39 | 2017-02-21 | 2026-06-17 |
Gastroesophageal Reflux (6) · Esophagitis (1)
BID protein, human (2) · Drug Interactions (2) · Lansoprazole (2) · Clarithromycin (1) · Didanosine (1) · Midazolam (1) · Omeprazole (1)
Sweden (4) · Bulgaria (2) · Czechia (2) · Georgia (2) · Hungary (2) · Poland (2) · Serbia (2) · Slovenia (2) · Germany (1) · Romania (1) · Ukraine (1) · United States (1)
Cornelia Lif-Tiberg, MD (1) · Erik Rein-Hedin, MD (1) · Karin Palm (1) · Tanja Turk, M.Pharm (1)
2025 (1)